- Home
- CMMB vs GIGM Comparison
CMMB vs GIGM Comparison
Compare CMMB & GIGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- GIGM
- Stock Information
- Founded
- CMMB 2004
- GIGM 1998
- Country
- CMMB Israel
- GIGM Taiwan
- Employees
- CMMB N/A
- GIGM N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- GIGM Computer Software: Programming Data Processing
- Sector
- CMMB Health Care
- GIGM Technology
- Exchange
- CMMB Nasdaq
- GIGM Nasdaq
- Market Cap
- CMMB 15.8M
- GIGM 14.5M
- IPO Year
- CMMB N/A
- GIGM 2000
- Fundamental
- Price
- CMMB $1.51
- GIGM $1.40
- Analyst Decision
- CMMB Strong Buy
- GIGM
- Analyst Count
- CMMB 3
- GIGM 0
- Target Price
- CMMB $5.67
- GIGM N/A
- AVG Volume (30 Days)
- CMMB 229.7K
- GIGM 12.4K
- Earning Date
- CMMB 11-07-2024
- GIGM 10-29-2024
- Dividend Yield
- CMMB N/A
- GIGM N/A
- EPS Growth
- CMMB N/A
- GIGM N/A
- EPS
- CMMB N/A
- GIGM N/A
- Revenue
- CMMB N/A
- GIGM $3,387,000.00
- Revenue This Year
- CMMB N/A
- GIGM N/A
- Revenue Next Year
- CMMB N/A
- GIGM N/A
- P/E Ratio
- CMMB N/A
- GIGM N/A
- Revenue Growth
- CMMB N/A
- GIGM N/A
- 52 Week Low
- CMMB $0.42
- GIGM $1.23
- 52 Week High
- CMMB $2.55
- GIGM $1.50
- Technical
- Relative Strength Index (RSI)
- CMMB 43.28
- GIGM 56.54
- Support Level
- CMMB $1.29
- GIGM $1.34
- Resistance Level
- CMMB $1.78
- GIGM $1.45
- Average True Range (ATR)
- CMMB 0.16
- GIGM 0.05
- MACD
- CMMB -0.05
- GIGM 0.00
- Stochastic Oscillator
- CMMB 36.73
- GIGM 58.82
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About GIGM GigaMedia Limited
GigaMedia Ltd is a publisher of online games. It has only one reportable segment, Digital Entertainment service. Digital Entertainment service business operates a portfolio of online games, mainly targeting online game players across Europe, and Asia, including Greater China and Southeast Asia. The company's portfolio of online games includes predominantly PC-based, non-cash gambling, or casino casual games, including MahJong and various card and table games. The company's product lines include MahJong, AkaSeka, Yume 100, Fun Vegas, and others. The company operates in Taiwan and Hong Kong.